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Abstract
Background: Glycaemia control (GC) remains an important therapeutic goal in critically ill patients. The enhanced
Model Predictive Control (eMPC) algorithm, which models the behaviour of blood glucose (BG) and insulin
sensitivity in individual ICU patients with variable blood samples, is an effective, clinically proven computer based
protocol successfully tested at multiple institutions on medical and surgical patients with different nutritional
protocols. eMPC has been integrated into the B.Braun Space GlucoseControl system (SGC), which allows direct data
communication between pumps and microprocessor. The present study was undertaken to assess the clinical
performance and safety of the SGC for glycaemia control in critically ill patients under routine conditions in
different ICU settings and with various nutritional protocols.
Methods: The study endpoints were the percentage of time the BG was within the target range 4.4 – 8.3 mmol.l−1,
the frequency of hypoglycaemic episodes, adherence to the advice of the SGC and BG measurement intervals.
BG was monitored, and insulin was given as a continuous infusion according to the advice of the SGC. Nutritional
management (enteral, parenteral or both) was carried out at the discretion of each centre.
Results: 17 centres from 9 European countries included a total of 508 patients, the median study time was 2.9 (1.9-6.1)
days. The median (IQR) time–in–target was 83.0 (68.7-93.1) % of time with the mean proposed measurement interval
2.0 ± 0.5 hours. 99.6 % of the SGC advices on insulin infusion rate were accepted by the user. Only 4 episodes (0.01 %
of all BG measurements) of severe hypoglycaemia <2.2 mmol.l−1 in 4 patients occurred (0.8 %; 95 % CI 0.02-1.6 %).
Conclusion: Under routine conditions and under different nutritional protocols the Space GlucoseControl system with
integrated eMPC algorithm has exhibited its suitability for glycaemia control in critically ill patients.
Trial registration: ClinicalTrials.gov NCT01523665
Keywords: Glycaemia control, Critically ill patients, Insulin protocol, Space Glucose Control, Enhanced Model Predictive
Control (eMPC)
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Background
Glycaemia control (GC) remains an important thera-
peutic goal in critically ill patients, despite an ongoing
debate regarding the optimum target ranges. The crucial
question is the appropriate intensity of glycaemic control
that can be accomplished safely. Risk of hypoglycaemia
is the most important concern in GC implementation;
therefore a protocolized approach, comprising a vali-
dated insulin administration protocol and use of accur-
ate monitoring technologies is essential for safe GC
management in intensive care patients. Standardizing
GC by a nurse-managed protocol has been found to im-
prove safety and efficiency [1]. In most intensive care
units (ICU), protocols for GC are still paper-based flow-
charts, using an “if-then” decision model [2, 3]. As
increasing complexity of insulin protocols reduces their
clarity for the user and increases the difficulty of their
use, paper-based protocols became converted into com-
puterized forms – from simple electronic algorithms to
clinical decision support systems (CDSS) with the ability
to predict insulin requirements based on patient-specific
response to previous doses as a function of their individ-
ual insulin resistance pattern. In addition to improved
GC, a computerized CDSS for GC has the potential to
simplify the work for nurses, reduce overall workload
and, most importantly, reduce the chance of human
error [4–7]. Although comparison of existing protocols is
difficult due to differences in processes and outcome mea-
sures, CDSSs generally achieve better GC with consist-
ently lower hypoglycaemia rates than paper-based systems
and appear to be superior in ICU patients [8–10].
The enhanced Model Predictive Control algorithm
(eMPC) developed by the CLINICIP (Closed Loop Insulin
Infusion in Critically Ill Patients) group [11] features a
variable sampling interval based on the accuracy of the
blood glucose (BG) prediction and is among those most
clinically proven and effective both in medical and surgical
ICU patients [10–12]. Being one of only a few predictive
algorithms it has been successfully implemented in
multiple institutions with different nutritional protocols
and on different ICU populations, including paediatric
patients.
The eMPC, as with other computerized algorithms,
has to be used on bedside computers, limiting its use.
Therefore the clinical application of the eMPC algo-
rithm, the B.Braun Space GlucoseControl system (SGC),
combines an effective algorithm with the advantages of
direct interconnection of all entry data - blood glucose
level, insulin rate and nutrition. SGC consists of three
infusion pumps (two for nutrition, one for insulin), con-
nected to a common station that allows data communi-
cation between the pumps and a central user interface
(Space Control). Space Control and the associated SGC
Module with the incorporated eMPC algorithm provide
suggestions for insulin rate and glucose measurement
interval.
Although SGC is already used in many ICUs world-
wide, there are few published experiences with the
use of the SGC system [13, 14], but none with its
routine use.
Even for the recently published study by Amrein et al.,
performed at two tertiary academic centres (Medical
University of Graz, Austria and the Medical University
of Zurich, Switzerland), all actively participating nurses
had to first attended a structured training before enrol-
ment of the first patient to familiarize with the handling
of the complete SGC system [15]. Therefore the object-
ive of this multicentre observational European study was
to describe the routine clinical performance and safety
of the SGC for GC in critically ill patients in different
ICU settings and also to test its ability to cope with vari-
ous nutritional protocols, enteral, parenteral or com-
bined. To ensure truly routine conditions, only those
centres where the SGC were already routinely used, par-
ticipated in this non-interventional study.
Methods
Study design
We conducted an observational multi-centre European
study to evaluate BG control in adult intensive care pa-
tients using the SGC system. This system incorporates
the eMPC algorithm to advise insulin titration for opti-
mal GC.
The primary objective of the study was to assess the
performance and efficiency of the SGC system for GC in
ICU patients under routine conditions. Secondary objec-
tives were the safety and usability of the SGC system.
The primary study endpoint was the percentage of time
within the target range (4.4 – 8.3 mmol.l−1), from the
start of the treatment to the last glucose measurement
under treatment. Initially two target ranges, 4.4-
6.1 mmol.l−1 and 4.4 – 8.3 mmol.l−1, were set for the
study, but based on the preference of each participating
ICU only the wider range (4.4 – 8.3 mmol.l−1) was fi-
nally used within the study. Secondary outcome mea-
sures were frequency of hypoglycaemic episodes for
safety evaluation, and adherence to the advice of the
SGC, BG measurement intervals and technical parame-
ters of the SGC (number of BG measurements outside
the predicted range generating a plausibility warning and
number of overruled insulin rate advices) for the SGC
system usability assessment.
The study was performed in accordance with the guide-
lines proposed in the Declaration of Helsinki and was sep-
arately and independently approved by ethics committees
of all participating institutions: Etická komise VFN v
Praze*/General University Hospital Prague, Czech Republic;
Etická komise FN Motol*/University Hospital in Motol,
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Prague, Czech Republic; Etická komise FN Plzeň*/
University Hospital in Plzen, Czech Republic; CEIC
Hospital ClínicoSan Carlos*/Capio Hospital Sur,
Madrid, Spain; Ethik-Kommission der Bayerischen
Landesartztekammer*/Klinikum Augsburg, Germany;
Etická komise FN Hradec Kralove*/University Hospital
Hradec Kralove, Czech Republic; Comitato Etico Azienda
Ospedaliera Universitaria Senese*/Azienda Ospedaliera
Universitaria Senese, Siena, Italy; Ethik-Kommission an
der Medizinischen Fakultat der Universitat Leipzig*/
Universität Leipzig, Germany; Comitato Etico Azienda
Ospedaliera Ospedale Civile Di Legnano*/Azienda
Ospedaliera di Legnano, Italy; Bioethics Committee of
Wroclaw Medical University/Wroclaw Medical University,
Poland; De Videnskabsetiske Komiteer for Region
Hovedstaden/Vejle Sygehus, Denmark; Den videnskab-
setiske komite i Region Hovedstaden/Rigshospitalet,
University of Copenhagen, Denmark; South-West -
Cornwall and Plymouth Research Ethics Committee/
Royal Cornwall Hospital, Truro, UK; Etikkommitten
Karolinska Universitetssjukhuset/Karolinska University
Hospital Solna, Stockholm, Sweden; Research Operational
& Governance Committee (ROC) on behalf of the Trust/
West Suffolk Hospital NHS Trust, Bury St Edmunds, UK;
Research Ethics Committee of the University of Tartu/
Tartu University Hospital, Estonia.
Written informed consent, obtained before inclusion,
or delayed consent from each patient or from a legal
surrogate, was requested by local ethics committees in 9
centres (marked by an asterisk), while in remaining 8
centres consent was waived because of the observational
nature of the study.
The study has been registered on January 26, 2012 at
the Clinical Trials Database (ClinicalTrials.gov Identifier:
NCT01523665).
Study population
Eligible patients were adult ICU patients who required
BG control by intravenous administration of insulin. Ex-
clusion criteria were all contraindications to intravenous
insulin therapy, decided by attending physicians. Only
those data that were obtained in routine clinical use
were recorded in the patient documentation sheet. No
additional measures (visits, tests, investigations) were re-
quired for this non-interventional study.
Observation time per patient was started with initi-
ation of the GC therapy using the SGC, i.e. the first BG
measurement entered into the device, and ended when
the GC therapy using the SGC system was finished. The
initiation of GC depended solely on the discretion of the
standard protocol of each participating ICU and was in-
dependent of the specific blood glucose value. Therefore
in a number of centres GC was initiated also in patients
without the presence of hyperglycaemia. The decisive
criterion for inclusion of the patient was the availability
of SGC at the time of GC initiation.
Sample size, countries and sites
The study was intended to be performed in 20 sites in 9
European countries to cover different local clinical prac-
tices and was planned to include 1000 patients or be ter-
minated on June 30, 2013 at the latest. Intensive care
departments where the SGC was already in use were
asked for participation. The number of patients included
in each centre thus also depended on the number of
SGC systems in use in each ICU.
Space GlucoseControl
The Space GlucoseControl system is a decision support
system for optimized insulin therapy for critically ill pa-
tients in a closely monitored environment, such as ICUs
or operating theatres. The system is based on the Space
pump platform. The SpaceControl touch screen, serving
as a central user interface, is connected to the SGC
module containing the self-learning eMPC algorithm. It
calculates the appropriate insulin rates by considering
the latest BG values together with the actual rates of en-
teral and parenteral nutrition. In addition, it determines
the time to next BG sample, based on the accuracy of
the blood glucose prediction. The SGC user can neglect
the decision as suggested by the SGC and/or at any time
decide to take an additional BG measurement. Within
the study the system was used in routine clinical practice
and according to its intended purpose and the instruc-
tions for use. All other aspects of patient care, including
nutritional management, were carried out at the discre-
tion of the treating clinicians. After the study termin-
ation the SGC users were asked to fill anonymously a
questionnaire related to efficiency of glycaemia control,
safety and workload.
Insulin administration
Insulin was given by a central venous catheter as a con-
tinuous infusion according to the suggestions of the
SGC. The medical staff always had the final decision to
accept the suggested insulin rate or not. The system
does not automatically change the rate of insulin on its
own without the involvement of a human being, requir-
ing a crosscheck by medical staff.
Blood glucose ranges, time in target range
The target range used within the study was 4.4 –
8.3 mmol.l−1. Severe hypoglycaemia was defined as blood
glucose of <2.2 mmol.l−1, the glycaemic range between
2.2 and 4.3 mmol.l−1 is reported as hypoglycaemia.
Hyperglycaemia was defined as blood glucose above
8.3 mmol.l−1.
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In order to obtain the percentage of time in each
range, the BG values were linearly interpolated. The per-
centage of time in relevant range was calculated from
linearly interpolated BG values for each patient separ-
ately by dividing the time in respective range with the
total study time for the patient (from the start of the
treatment to the last glucose measurement under
treatment), and then multiplying by 100.
Blood sampling
Blood glucose was monitored according to the sugges-
tions of the SGC with variable sample interval. Blood
samples for glucose measurement were obtained by
means of arterial catheters whenever possible or central
venous catheters; the use of capillary samples was dis-
couraged but not forbidden. BG levels were measured
with the use of blood gas or point-of-care analysers or
central laboratory analysers based on routine use at each
centre.
Data documentation
With the first BG measurement that was entered into
the SGC system, all entered BG values, the insulin infu-
sion rate, the enteral/parenteral carbohydrate feeding
rates of the pumps connected to the system and the sug-
gestions by the eMPC algorithm were automatically re-
corded in the system log-files. After the SGC therapy of
a patient was finished, the therapy log file of the SGC
was exported by the local study coordinator at each in-
stitution via SpaceCOM on an USB data storage device
and then via a secured web-based study interface into
the study database.
The following parameters were recorded at the start of
the SGC therapy: patient demographics (age, sex, height,
and weight), APACHE II score, history of diabetes, ad-
mission diagnosis and concomitant diseases. After the
SGC therapy of a patient was finished, source of blood
for glucose measurements, BG measurement device,
adverse device effects, reason for overruling the advice
of the SGC and reasons for discontinuation of SGC ther-
apy were manually entered in a web-based observational
documentation sheet for each patient. The data that had
to be entered manually were checked for completeness
and plausibility. Finally completed web-based patient
documentation sheets and the corresponding SGC log-
file were validated by the data manager. If necessary,
data clarification requests were sent to the investigator.
Statistical analysis
All patients who received intravenous insulin using the
advice of the SGC at least once and had a validated SGC
log-file with completed documentation were included in
the analysis. Unevenly distributed continuous variables
are presented as medians and interquartile ranges (IQR),
and normally distributed data as means ± standard devi-
ation (SD). Categorical data are given as a number ( %).
The percentage of time within the predefined glucose
target range (4.4-8.3 mmol/l) was defined as primary
endpoint for the assessment of SGC performance and ef-
ficiency. Frequency of hypoglycaemic episodes was set as
secondary endpoint for safety evaluation; BG measure-
ment intervals and acceptance of SGC advices on insulin
infusion rate for system usability assessment. The
following standard procedures for the comparison of
subgroups were used: Fisher’s exact test for binary data,
chi-squared test for kx2 tables (k > 2), U test according
to Wilcoxon-Mann–Whitney, t-test for metric data,
ANOVA (analysis of variance). All statistical tests were
performed two-tailed with the pre-specified significance
level of α = 5 %. An interim analysis to check the proto-
col safety (frequency of hypoglycaemic episodes) was
performed after 300 patients. Data analysis was per-
formed using SPSS® version 19 (SPSS Inc., Chicago, IL).
Results
Study participants
17 centres from 9 European countries included overall
508 patients with complete study documentation. The
first patient was included on June 27, 2011 and the last
patient finished on July 26, 2013. The patients’ demo-
graphic characteristics, history of diabetes, APACHE II
score, admission diagnosis and entry BG are shown in
Table 1. There were no significant differences between
the study centres in anthropometrical data (age, gender,
height, weight and BMI of the patients), but the centres
differed significantly in main admission diagnosis, num-
ber of diabetic patients (32 - 78 %; median 46 %), and
entry BG levels (3.4 - 40 mmo/l; median 9.3 mmo/l).
Blood glucose measurement
Blood samples for glucose measurement were obtained
by means of arterial catheters (61 %) and central venous
catheters (27 %) or as capillary samples (12 %). BG levels
were measured with point-of-care (58 %) or blood gas
(42 %) analyzers. Central laboratory analyzer was used in
one patient only.
Blood glucose Level
All study patients were assigned to the target range of
4.4 - 8.3 mmol.l−1. The GC characteristics are shown in
Table 2. 300 (59 %) patients started with BG level higher
than 8.3 mmol.l−1, while 204 (40.2 %) had BG level
within target range at the start of insulin therapy. In 4
patients the SGC was initialized when BG level was
below 4.4 mmol.l−1. In patients with entry BG level
higher than 8.3 mmol.l−1 the median time to target
range was 4.5 hours (IQR 2.3-8.3), in 7 (2.3 %) pa-
tients the target BG was not achieved during the
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study period. The total study time varied from 2 hours
to 54 days.
There was significant correlation (p < 0.001) be-
tween the entry BG level and the time to reach
target range (Fig. 1). Good performance and safety of
the system was observed with respect to both time
in target range and incidence of hypoglycaemic
episodes - only 4 severe hypoglycaemias in 4 patients
(0.8 %; 95 % CI 0.02-1.6 %), representing 0.14
events/1000 measurements, were recorded in the
entire study (Fig. 2).
Technical parameters of the SGC system performance
A total of 29575 blood samples were drawn and corre-
sponding number of recommendations for time to next
sample were rendered by the SGC system during the
whole study period. Mean proposed next measurement
time was 2.0 ± 0.5 hours of which 0.15 % was shorter
than 30 min, 46.6 % in the range 30–90 min, 22.7 % in
the range 91–150 min, 12.3 % in the range 151–210 min
and 18.4 % was longer than 210 min.
From the total of 29575 entered BG values 1176 (4 %)
were found by SGC as not plausible (outside the range
of the predicted BG level) and the SGC displayed an on-
screen warning. 591 (50 %) of these warnings were be-
cause of unexpectedly too low, and 585 (50 %) because
of unexpectedly too high BG values.
Based on BG values and nutrition changes the SGC
gave a total of 30332 insulin infusion rate advisories. 118
of these were not accepted by the user – in 75 cases the
insulin rate was adjusted downwards and in 43 cases up-
wards compared to the recommendations of the SGC
system.
Nutrition
Nutritional management was carried out at the discre-
tion of the each participating centre and treating clini-
cians. The amount of carbohydrates given to the study
patients is shown in Table 3.
Table 1 Patients baseline characteristics and admission
diagnosis
Patients characteristics (N = 508)
Female 198 (39.0)
Male 310 (61.0)
Age [years] 65.6 ± 12.9
Height [m] 1.70 ± 0.1
Weight [kg] 85.1 ± 20.5
BMI [kg/m2] 29.0 ± 6.5
BMI above 25 kg/m2 375 (73.8)
BMI above 30 kg/m2 184 (36.2)
APACHE II [points] 21.1 ± 7.4
BG level at study entry [mmol/l] 10.6 ± 5.6
History of Diabetes
Total 280 (55.1)
Type 1 33 (6.5)
Type 2 244 (48.0)
Other 3 (0.6)
Admission diagnosis
Heart insufficiency 152 (29.9)
Respiratory insufficiency 104 (20.5)
Sepsis, septic shock 63 (12.4)
Gastrointestinal disease, bleeding 38 (7.5)
Diabetes, diabetic ketoacidosis 21 (4.1)
Acute pancreatitis 21 (4.1)
Cerebral hematoma, bleeding, infarction 19 (3.7)
Myocardial infarction 14 (2.8)
Vascular diseases 11 (2.2)
Renal insufficiency 11 (2.2)
Liver diseases 10 (2.0)
Infections 8 (1.6)
Meningitis/ Encephalitis 6 (1.2)
Other 30 (5.9)
Data are presented as mean ± standard deviation or number (%). APACHE
II = Acute Physiology and Chronic Health Evaluation II Score, BMI = body
mass index
Table 2 Blood glucose control characteristics
Blood glucose control characteristics Number
Total study time [days] 508 2.9 (1.9–6.1)
Blood glucose level at entry [mmol.l−1] 508 9.3 (6.8–12.3)
Time to reach target range [hours] 293 4.5 (2.3–8.3)
Mean insulin infusion rate [U/h] 508 3.3 (2.3–5.1)
Whole study period
Mean blood glucose level [mmol.l−1] 508 6.9 (6.6–7.7)
Severe hypoglycaemia <2.2 mmol.l−
[Number of patients/number of episodes]
508 4 (0.8)/4 (0.01)
Hypoglycaemia (2.2–4.3 mmol.l−1)
[% of time]
271 0.2 (0–1.4)
Target range [% of time] 508 83.0 (68.7–93.1)
Hyperglycaemia >8.3 mmol.l−1 [% of time] 485 14.7 (6.1–29.5)
After reaching target range
Mean blood glucose level [mmol.l−1] 501 6.9 (6.6–7.2)
Severe hypoglycaemia <2.2 mmol.l−1
[Number of patients/number of episodes]
508 4 (0.8)/4 (0.01)
Hypoglycaemia (2.2–4.3 mmol.l−1)
[% of time]
269 0.2 (0.0–1.4)
Target range [% of time] 501 88.2 (77.5–95.1)
Hyperglycaemia >8.3 mmol.l−1 [% of time] 437 10.5 (3.4–20.4)
Data are presented as median (IQR) or number (%)
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348 patients (68.5 %) received enteral nutrition; 287 as
an infusion and 61 as a bolus at any time of the study.
Parenteral carbohydrates were prescribed to 417 pa-
tients; in 340 cases as continuous infusions and in 77 as
boluses.
Users’ opinion
The SGC users (ICU nurses) were anonymously ques-
tioned after study termination about their opinion on
the use of the SGC. Questions were related to efficiency
of GC, safety and workload. The questionnaire was com-
pleted by a total of 170 ICU nurses. The answers to par-
ticular questions are shown in Table 4.
Discussion
The objective of the present observational study was to
assess the performance of the Space GlucoseControl
system under routine clinical conditions in different
European ICUs with different nutritional protocols. We
observed very good performance of the system - 83 % of
the time BG was maintained in the target range, and
after reaching the target range even in 88 % of the time.
On the other hand in 7 (2.3 %) patients the target BG
range was not ever achieved during the study period.
The incidence of hypoglycaemias was very low (0.2 %),
demonstrating a good safety level. For comparison, a
computer-assisted protocol used in the NICE-SUGAR
trial, based on a complex decision tree had a hypo-
glycaemia rate of 6.8 % [16, 17].
Although SGC is already used in many ICUs world-
wide, there are only few shared experiences with the use
of this system [13–15]. In addition, the published data
come from feasibility or testing studies. It is known that
the results of such studies are often more optimistic
than the results achieved under routine clinical condi-
tions. Therefore the safety and effectiveness under clin-
ical rather than study conditions are fundamental for
safe GC management. Risk of hypoglycaemia is one of
the most discussed issues in this field of critical care. In
our study hypoglycaemia (<2.2 mmol.l−1) occurred in
only 4 patients (0.8 %), representing 0.01 % of the time.
Compared to the large clinical trials (Leuven studies,
VISEP and NICE-SUGAR), where hypoglycaemia was
frequent (from 5.1 up to 17 %)[16, 18–20], this is ex-
tremely low. From this perspective, the results of our
study perhaps exceeded expectations. If we compare the
achieved time in the target range in this study with the
study by Amrein et al. performed in Graz and Zurich
[15], the performance of the SGC under truly routine
clinical conditions was exceptional as the time in target
range 4.4 to 8.3 mmol/l was reached in both studies in
88 %. The same applies for the occurrence of moderate
or severe hypoglycaemia.
Beside the predictive eMPC algorithm a key advantage
of SGC is the direct interconnection of the algorithm
with the standard infusion pumps - insulin and both en-
teral and parenteral nutrition. As one of the most com-
mon causes of severe hypoglycaemia in the ICU is a
Fig. 1 Correlation between entry blood glucose level and time to
reach the target range. (Pearson Correlation)
Fig. 2 Time in target range. Time in each blood glucose range (mmol/l)
for the entire study period (black) and from the first time in target range
(white). Data are presented as median (IQR)
Table 3 Overview on enteral and parenteral nutrition
Nutrition (carbohydrates)
Enteral nutrition
Enteral bolus [g] (N = 61; 12.0 %) 1.3 (0.5–57)
Enteral infusion [g/kg/day] (N = 287; 56.2 %) 2.1 (1.4–2.8)
Time with enteral infusion [% of total study time] 81.2 (58.7–94.7)
Parenteral nutrition
Parenteral bolus [g] (N = 77; 15.2 %) 4.0 (0.5–10)
Parenteral infusion [g/kg/day] (N = 340; 66.9 %) 1.8 (1.2–2.7)
Time with parenteral infusion [% of total study time] 89.0 (60.9–97.3)
Total nutrition
Enteral/parenteral [g/hour] (N = 464; 91.3 %) 7.2 (4.7–9.6)
Data are presented as median (IQR)
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reduction in, or switching off of nutrition without proper
adjustment of the rate of insulin [21], this connection is
crucial to safety. The incidence of hypoglycaemic events
with SGC is the lowest incidence of severe hypo-
glycaemia of all comparable studies, including those with
eMPC algorithm [3, 10, 11, 14], albeit allowing for a
narrower target range (4.4 – 6.1 mmol.l−1) in these trials.
The comparison of existing insulin protocols is difficult,
as the overall clinical settings including target ranges
vary considerably between the studies. Therefore, the
findings of such comparisons are rather speculative. For
comparison with the SGC come into consideration
mainly three other CDSS: the Glucommander - a web-
based insulin nomogram, the GRIP (Glucose Regulation
for Intensive care Patients) - a stand-alone Java based
program, and EndoTool Glucose Management System -
a predictive and adaptive software system for critical
care setting. The Glucommander was invented in 1984
and is used in a number of mainly US and Canada
hospitals [22]. In a study by Yamashita et al. the
Glucommander maintained BG within the target range
of 5.1–8.0 mmol/l for 53 % of the time and with
hypoglycaemia occurred in 3.7 % from all BG measure-
ments [23]. The performance of the GRIP seemed to be
better, but at the first sight only. The fraction of time
with BG between 4 and 7.5 mmol/l was 78 %, but with
hypoglycaemia (<3.5 mmol/l) in 11 % of patients [24]!
Similarly, with the EndoTool the percentage of BG
measurements in the target range 4.4–8.3 mmol/l was
70.4 % and they experienced 7 hypoglycaemic events in
141 patients (vs. 4 events/508 patients in our study) [25].
Compare to these results the performance of the SGC in
our study has shown somewhat superior efficiency with
time in target range 83 % and also the safety with
hypoglycaemia only 0.2 % of all measurements. Previous
may also apply for other potential head-to-head compar-
isons with latest insulin protocol studies with similar
target range: Software-guided insulin dosing protocol
used by Saur and colleagues maintained glycaemia 68 %
of time in the target range 5.3 -7.5 mmol/l with
hypoglycaemia of 0.5 % [26]. SPRINT (Specialized
Relative Insulin and Nutrition Tables) protocol, used at
Hungarian ICU, achieved 77.6 % of BG measurements in
the target range 4.0-8.0 mmol/l with 1.9 % of the
BG <4.0 mmol/l [27]. And finally, with GlucoCare-
directed Yale 100–140 mg/dL protocol targeted to
5.6-7.8 mmol/l the incidence of hypoglycaemia was
1.1 % of readings and 17.6 % of patients [28]. Comparison
with other CDSS is rather impossible as their input condi-
tions, measures and target ranges already differ too much.
An important verification of the SGC effectiveness and
safety was its use under different ICU settings and with
various nutritional protocols. As the intention of this
study was to test the SGC under routine conditions, the
feeding of patients was not standardized and nutritional
management was carried out at the discretion of each
participating centre. Hence a number of different nutri-
tional protocols were used within the study. Regardless
of the nutrition practices, the SGC algorithm coped
safely with all of these variations. This versatility is
achieved using a model of the glucoregulatory system
within the eMPC, which adapts itself to the input–output
relationship observed during GC. Incoming glucose mea-
surements are used by the model to update model param-
eters such as insulin sensitivity, taking into account
previously given insulin and parenteral and enteral carbo-
hydrates. Once individualized to a critically ill subject, the
eMPC uses the glucoregulatory model to determine the
optimum insulin infusion rate to achieve the target glu-
cose concentration.
The risk of human error is an important safety issue.
Medication errors occur frequently with both paper-
based and computerized protocols and play a major part
in overall patient safety. In a retrospective study by
Campion et al. over 5 % of BG values entered into the
protocol did not match values from the analyser [29].
Other investigators have also reported rates of nurse
protocol override, or deviation from system recommen-
dations, ranging from 2 % to 23 % [29–32]. It is obvious
that mismatched BG values can significantly influence
Table 4 Questionnaire. SGC users were questioned after the termination of the study (N = 170)
How well was the patient’s blood glucose stabilised in the target range? Excellent Good Fair Adequate Poor
15 % 61 % 16 % 6 % 2 %
Do you think that control of the patient’s blood glucose was maintained more effectively by the use of the SGC
system compared with normal practice?
Yes No
74 % 26 %
Is the SGC system user friendly? 83 % 17 %
Did you feel confident using the SGC system? 81 % 19 %
Do you think that using the SGC system can help to avoid making mistakes when controlling the blood glucose? 77 % 23 %
How did you rate your work load using the SGC system compared with
normal practise?
Decreased Slightly decreased Equal Slightly increased Increased
1 % 2 % 6 % 31 % 60 %
Data are presented as %
SGC Space GlucoseControl
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protocol performance, both paper-based and computer-
ized. From this perspective another advantage of the
SGC is the prediction of the next BG level. The eMPC
uses a model of the glucoregulatory system to predict a
value of the next glucose measurement, taking into ac-
count individual insulin sensitivity and nutrition. If the
entered value considerably differs from the predicted,
the SGC evaluates this as not plausible and displays on-
screen warning. In our study 4 % of entered BG values
were found by the SGC as not plausible and the SGC
asked for confirmation of the entered value, eventually
recommending repeat measurement. Half of these
warnings were because of unexpectedly too low BG, and
half because of unexpectedly too high BG. A false
hypoglycaemia would "only" risk exposing the patient to
hyperglycaemia, however, a false hyperglycaemia exposes
the patient to a risk of potentially severe hypoglycaemia
as a result of increased insulin rate.
The acceptance of a therapy protocol by the critical
care team (nurses as well as physicians) is a prerequisite
for its successful implementation. Although this issue
was not addressed in this study, data from the literature
dealing with strategies of change management confirm
this [33]. The complexity of critical care recommends
therapeutic interventions that are easy to perform with a
high level of safety and reproducibility. A computer
assisted approach can fulfil these criteria. A recent pub-
lished study comparing a paper-based with software
driven protocol confirms the superiority of a computer
assisted protocol in terms of sustained GC. However, the
frequency of BG measurement increased nearly two-fold
[26]. In our study the average interval between measure-
ments was 2.02 hours. About 4 % of measurements were
not plausible, resulting in the device recommending a
repeat measurement and increasing the nurse workload.
Although the implementation of SGC was on most ICUs
associated with an increased workload for nurses, com-
pared to their normal practice they evaluated improved
effectiveness with the SGC highly positively, and mainly
reported increased safety with respect to making mis-
takes when controlling the blood glucose in their pa-
tients. As the median stay in the study was only
2.9 days, frequent measurements might have been due
to an unstable metabolism and insulin sensitivity in the
early phase of critical illness. Further investigation of this
device in patients with a long stay in the ICU is needed.
A limitation of our study is the use of different tech-
nologies for BG monitoring, including point-of-care,
blood gas and central laboratory analyzers. However, the
study was a pragmatic one designed to test SGC under
routine conditions and this just emulates the routine
practices in the ICUs and confirms the SGC perform-
ance in routine conditions. The same applies for the
sampling sites for the measurement of BG. A potential
future application of this system will be its connection
to continuous glycaemic sensors. Feasibility studies have
already shown a good performance of the eMPC algo-
rithm in such an application [34].
Conclusions
The Space GlucoseControl system with integrated eMPC
algorithm has under routine conditions exhibited its
suitability for blood glucose control in critically ill med-
ical and surgical patients. Similarly, very low incidence
of hypoglycaemias (0.2 %), acceptance of various nutri-
tional protocols and only 0.4 % of recommendations not
accepted by the user demonstrate its usefulness for rou-
tine blood glucose management under different ICU set-
tings. It remains to be elucidated which cohort of
patients (medical or surgical, type of surgery, type of nu-
trition, duration of stay, etc.) would benefit most from
the application of the SGC.
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